Reneo Pharmaceuticals, Inc. (RPHM)

USD 18.2

(952.02%)

Market Cap (In USD)

60.84 Million

Revenue (In USD)

-

Net Income (In USD)

-77.38 Million

Avg. Volume

169.34 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.68-82.9
PE
-
EPS
-
Beta Value
0.22
ISIN
US75974E1038
CUSIP
75974E103
CIK
1637715
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Gregory J. Flesher
Employee Count
-
Website
https://reneopharma.com
Ipo Date
2021-04-08
Details
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.